Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase C𝛃 inhibitor

References

• Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008;19:841–858.
   PubMed Web of Science ®Google Scholar
• Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277–285.
   PubMed Web of Science ®Google Scholar
• Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010;116:1165–1176.
   PubMed Web of Science ®Google Scholar
• Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997;24:70–82.
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589–596.
   PubMed Web of Science ®Google Scholar
• Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev 2003;29:3–10.
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535–1548.
   PubMed Web of Science ®Google Scholar
• Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005;105:3434–3441.
   PubMed Web of Science ®Google Scholar
• Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs 2008;17:939–944.
   PubMed Web of Science ®Google Scholar
• Jian W, Yamashita H, Levitt JM, Lerner SP, Sonpavde G. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther 2009;8:1772–1778.
   PubMed Web of Science ®Google Scholar
• Jiang XH, Tu SP, Cui JT, et al. Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis. Cancer Res 2004;64:5787–5794.
   PubMed Web of Science ®Google Scholar
• Rieger J, Lemke D, Maurer G, et al. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem 2008;106:2436–2448.
   PubMed Web of Science ®Google Scholar
• Spindler KL, Lindebjerg J, Lahn M, Kjaer-Frifeldt S, Jakobsen A. Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer. Int J Colorectal Dis 2009;24:641–645.
   PubMed Web of Science ®Google Scholar
• Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 2008;99:750–759.
   PubMed Web of Science ®Google Scholar
• Vogl UM, Berger W, Micksche M, et al. Synergistic effect of sorafenib and sunitinib with enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Lett 2009;277:218–226.
   PubMed Web of Science ®Google Scholar
• Holler C, Pinon JD, Denk U, et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009;113:2791–2794.
   PubMed Web of Science ®Google Scholar
• Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004;101:3118–3123.
   PubMed Web of Science ®Google Scholar
• Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res 2007;55:477–486.
   PubMedGoogle Scholar
• Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641–1647.
   PubMed Web of Science ®Google Scholar
• Raab MS, Breitkreutz I, Tonon G, et al. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2009;113:1513–1521.
   PubMed Web of Science ®Google Scholar
• Reyland ME. Protein kinase C and apoptosis. Apoptosis, cell signaling and human disease. In: Srivastava R, editor. Totowa, NJ: Humana Press, Inc; 2007. pp 31–55.
   Google Scholar
• Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783–1789.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-$132#cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Verdelli D, Nobili L, Todoerti K, et al. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol Oncol 2009;27:23–30.
   PubMed Web of Science ®Google Scholar
• Guo B, Su TT, Rawlings DJ. Protein kinase C family functions in B-cell activation. Curr Opin Immunol 2004;16:367–373.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol 2008;45:S11–S16.
   PubMed Web of Science ®Google Scholar
• Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol 2007;19:590–595.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247–253.
   PubMed Web of Science ®Google Scholar
• Schaffel R, Morais JC, Biasoli I, et al. PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma. Mod Pathol 2007;20:326–330.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741–1746.
   PubMed Web of Science ®Google Scholar
• Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008;49:1374–1383.
   PubMed Web of Science ®Google Scholar
• Shinohara H, Maeda S, Watarai H, Kurosaki T. IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J Exp Med 2007;204:3285–3293.
   PubMedGoogle Scholar
• Su TT, Guo B, Kawakami Y, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3:780–786.
   PubMed Web of Science ®Google Scholar
• Deacon EM, Pongracz J, Griffiths G, Lord JM. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol 1997;50:124–131.
   PubMedGoogle Scholar
• Choi PM, Tchou-Wong KM, Weinstein IB. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol Cell Biol 1990;10:4650–4657.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sagawa S, Hoshi J, et al. Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett 2004;14:5171–5174.
   PubMed Web of Science ®Google Scholar
• Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998;273:33533–33539.
   PubMed Web of Science ®Google Scholar
• Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321–328.
   PubMed Web of Science ®Google Scholar
• Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541–6551.
   PubMed Web of Science ®Google Scholar
• Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998;279:710–714.
   PubMed Web of Science ®Google Scholar
• Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785–789.
   PubMed Web of Science ®Google Scholar
• Serova M, Ghoul A, Benhadji KA, et al. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol 2006;33:466–478.
   PubMed Web of Science ®Google Scholar
• Li ZY, Liu DP, Liang CC. New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia 2005;19:183–190.
   PubMed Web of Science ®Google Scholar
• Khwaja A. Akt is more than just a Bad kinase. Nature 1999;401:33–34.
   PubMed Web of Science ®Google Scholar
• Lee KW, Kim SG, Kim HP, et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008;68:1916–1926.
   PubMed Web of Science ®Google Scholar
• Kim SG, Lee SJ. PI3K, RSK, and mTOR signal networks for the GST gene regulation. Toxicol Sci 2007;96:206–213.
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462–7469.
   PubMed Web of Science ®Google Scholar